Who
Carman Alenson
Officer
Company insider
Files Form 4 as: Officer, Prime Medicine; Principal Accounting Officer, Agios Pharmaceuticals.
In numbers
- Trades disclosed
- 69
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $773K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 7 Nov 2016
- Last trade
- 23 Feb 2026
- Last filed
- 24 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Feb 2026filed 24 Feb 2026 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 23 Feb 2026filed 24 Feb 2026 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code D | —16,083 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,083 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code D | —90,498 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,498 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code D | —6,254 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,254 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code D | —90,498 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,498 | filing |
| 27 Feb 2025filed 3 Mar 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,500 at $0.00 | filing |
| 21 Feb 2024filed 23 Feb 2024 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,498 at $0.00 | filing |
| 18 Apr 2023filed 20 Apr 2023 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,254 at $0.00 | filing |
| 31 Mar 2023filed 4 Apr 2023 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,498 at $0.00 | filing |
| 21 Jun 2021filed 23 Jun 2021 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $92K1,777 at $51.51 | filing |
| 21 Jun 2021filed 23 Jun 2021 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $109K1,777 at $61.61 | filing |
| 21 Jun 2021filed 23 Jun 2021 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,777 at $0.00 | filing |
| 16 Apr 2021filed 20 Apr 2021 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $62K1,118 at $55.89 | filing |
| 15 Apr 2021filed 16 Apr 2021 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $54K991 at $54.00 | filing |
| 22 Feb 2021filed 24 Feb 2021 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —692 at $0.00 | filing |
News
Contrasting Revolution Medicines (NASDAQ:RVMD) and Agios Pharmaceuticals (NASDAQ:AGIO)AGIO · themarketsdaily.com · 22 Oct 2026
0 headlines in the last 90 days name Carman Alenson; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.